Medicover Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Fredrik Rågmark

Chief executive officer

€2.6m

Total compensation

CEO salary percentage	39.0%
CEO tenure	27.3yrs
CEO ownership	1.0%
Management average tenure	3.8yrs
Board average tenure	14.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Fredrik Rågmark's remuneration changed compared to Medicover's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	€22m
Dec 31 2023	n/a	n/a	€18m
Sep 30 2023	n/a	n/a	€8m
Jun 30 2023	n/a	n/a	€6m
Mar 31 2023	n/a	n/a	€2m
Dec 31 2022	€3m	€1m	€12m
Sep 30 2022	n/a	n/a	€37m
Jun 30 2022	n/a	n/a	€59m
Mar 31 2022	n/a	n/a	€88m
Dec 31 2021	€2m	€952k	€102m
Sep 30 2021	n/a	n/a	€93m
Jun 30 2021	n/a	n/a	€90m
Mar 31 2021	n/a	n/a	€52m
Dec 31 2020	€2m	€670k	€26m
Sep 30 2020	n/a	n/a	€14m
Jun 30 2020	n/a	n/a	€4m
Mar 31 2020	n/a	n/a	€16m
Dec 31 2019	€1m	€900k	€23m
Sep 30 2019	n/a	n/a	€19m
Jun 30 2019	n/a	n/a	€19m
Mar 31 2019	n/a	n/a	€20m
Dec 31 2018	€1m	€807k	€22m
Sep 30 2018	n/a	n/a	€28m
Jun 30 2018	n/a	n/a	€26m
Mar 31 2018	n/a	n/a	€23m
Dec 31 2017	€921k	€810k	€19m

Compensation vs Market: Fredrik's total compensation ($USD2.79M) is about average for companies of similar size in the UK market ($USD2.33M).

Compensation vs Earnings: Fredrik's compensation has been consistent with company performance over the past year.

CEO

Fredrik Rågmark (60 yo)

27.3yrs

Tenure

€2,602,000

Compensation

Mr. Fredrik Ragmark serves as the Chief Executive Officer of Medicover AB (publ). Mr. Ragmark has been employed with Medicover since 1996. He serves as Managing Director and Board Member of Kalvskär AB.Fr...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Fredrik Rågmark	CEO & Director	no data	€2.60m	1.05% € 271.5m
Joe Ryan	Chief Financial Officer	no data	no data	0.92% € 238.6m
Jaroslaw Urbanczyk	Chief Information Officer	4.6yrs	no data	0.0040% € 1.0m
Hanna Bjellquist	Head of Investor Relations	no data	no data	no data
Jenny Brandt	General Legal Counsel	no data	no data	0.035% € 9.1m
Andrew Vallance-Owen	Chief Marketing Officer	no data	no data	no data
Kamila Skorupinski	Group Chief People Officer	less than a year	no data	no data
John Stubbington	Chief Operating Officer of Healthcare Services	8.3yrs	no data	0.49% € 126.2m
Staffan Ternstrom	Chief Operating Officer for Diagnostic Services	2.9yrs	no data	0.033% € 8.7m

3.8yrs

Average Tenure

58yo

Average Age

Experienced Management: 0RPS's management team is considered experienced (3.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Fredrik Rågmark	CEO & Director	27.3yrs	€2.60m	1.05% € 271.5m
Robert Jochnick	Independent Director	17.3yrs	€54.60k	1.22% € 315.9m
Fredrik Stenmo	Independent Chairman	19.3yrs	€101.50k	4.42% € 1.1b
Margareta Nordenvall	Independent Director	23.3yrs	€66.20k	0.060% € 15.6m
Arno Bohn	Independent Director	23.3yrs	€63.05k	0.20% € 52.1m
Cecil Michael Flemming	Independent Director	9.3yrs	€78.30k	no data
Anne Berner	Independent Director	2.1yrs	€59.85k	no data
Azita Shariati	Independent Director	2.1yrs	€63.05k	0.0015% € 381.9k
Peder Jochnick	Independent Director	12.3yrs	€54.60k	2.6% € 674.4m
Sonali Chandmal	Independent Director	7.3yrs	€71.45k	0.017% € 4.3m

14.8yrs

Average Tenure

59.5yo

Average Age

Experienced Board: 0RPS's board of directors are seasoned and experienced ( 14.8 years average tenure).

Medicover Management

Management criteria checks 4/4

Key information

Recent management updates

Insider recently bought kr1.8m worth of stock

Medicover Appoints Kamila Skorupinski as Chief People Officer as of 1 April 2024

Independent Chairman recently bought kr3.9m worth of stock

Medicover AB (Publ) Announces Resignation of Joe Ryan as Chief Financial Officer

Independent Director recently bought kr303k worth of stock

Medicover AB (publ) Announces Nomination Committee for the Annual General Meeting 2024

Recent updates

Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025

First quarter 2024 earnings released: EPS: €0.041 (vs €0.01 in 1Q 2023)

Upcoming dividend of €0.12 per share

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: €0.12 (vs €0.079 in FY 2022)

Dividend of €0.12 announced

Insider recently bought kr1.8m worth of stock

Full year 2023 earnings released: EPS: €0.12 (vs €0.081 in FY 2022)

Now 22% undervalued

Medicover AB (publ) Provides Earnings Guidance for the Financial Year 2025

Medicover Appoints Kamila Skorupinski as Chief People Officer as of 1 April 2024

Independent Chairman recently bought kr3.9m worth of stock

Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025

Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025

Third quarter 2023 earnings released

Medicover AB (Publ) Announces Resignation of Joe Ryan as Chief Financial Officer

Independent Director recently bought kr303k worth of stock

Medicover AB (publ) Announces Nomination Committee for the Annual General Meeting 2024

Medicover AB (publ), Annual General Meeting, Apr 26, 2024

Independent Director recently bought kr1.4m worth of stock

Independent Chairman recently bought kr6.3m worth of stock

Second quarter 2023 earnings released: EPS: €0.037 (vs €0.01 in 2Q 2022)

Medicover AB (publ) to Report Q1, 2024 Results on Apr 26, 2024

Insider recently bought kr242k worth of stock

Chief Information Officer recently bought kr321k worth of stock

Upcoming dividend of €0.12 per share at 0.7% yield

Full year 2022 earnings released

Now 24% undervalued

Full year 2022 earnings released

Medicover AB (publ) Proposes Dividend for 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released

Medicover AB (publ) to Report Q2, 2023 Results on Jul 26, 2023

Medicover AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Medicover AB (publ) (OM:MCOV B) acquired Übag Mvz Meindentist Gbr.

Medicover AB (publ) (OM:MCOV B) completed the acquisition of Laurus Medical SRL.

Medicover AB (publ), Annual General Meeting, Apr 27, 2023

Second quarter 2022 earnings released

Independent Chairman recently bought kr2.8m worth of stock

Medicover AB (publ) (OM:MCOV B) acquired Konzilijum.

Investor sentiment deteriorated over the past week

Medicover AB (publ) (OM:MCOV B) signed an agreement to acquire Übag Mvz Meindentist Gbr.

High number of new directors

Medicover AB (publ) (OM:MCOV B) acquired Kliniki Terapii Allenort Holding Sp. z o.o.

Independent Chairman recently bought kr3.3m worth of stock

Medicover AB (Publ) Elects Anne Berner and Azita Shariati as Board Members

Full year 2021 earnings released: EPS: €0.69 (vs €0.18 in FY 2020)

Insufficient new directors

Upcoming dividend of €0.12 per share

Full year 2021 earnings released: EPS: €0.69 (vs €0.18 in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

General Legal Counsel recently bought kr518k worth of stock

Now 24% undervalued after recent price drop

Medicover AB (publ) Proposes Dividend for the Financial Year 2021, Expected Payable on 6 May 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Medicover AB (publ) (OM:MCOV B) acquired an unknown majority stake in Mediplus Clinic.

Investor sentiment deteriorated over the past week

Chief Financial Officer recently sold kr1.4m worth of stock

Independent Director recently sold kr2.9m worth of stock

Third quarter 2021 earnings released

Medicover AB (publ) (OM:MCOV B) acquired 70% stake in Klinikk Hanne As for €18.2 million.

Medicover AB (publ) (OM:MCOV B) acquired 88.8% stake in Sellmerdiers Aps from Liza Diers and Anette Sellmer for €13.7 million.

Second quarter 2021 earnings released: EPS €0.20 (vs €0.056 loss in 2Q 2020)

Chief Information Officer recently bought kr109k worth of stock

Chief Information Officer recently bought kr161k worth of stock

Chief Information Officer recently bought kr161k worth of stock

First quarter 2021 earnings released